Clinical Trial Update: Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluates adding anlotinib to standard carboplatin/paclitaxel chemotherapy as first-line therapy for advanced ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Wenjun Cheng | Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING